Your session is about to expire
← Back to Search
Study Summary
This trial will study a new drug to see if it is safe and effective in treating patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any serious, uncontrolled illnesses or infections.I have had cancer before, but it was a long time ago.I have a history of serious heart problems.I am fully active or can carry out light work.I have or am at risk for eye damage affecting my retina.My organs are working well.I have a history of myelodysplastic syndrome or acute myeloid leukemia.I have not taken any cancer treatments recently before starting UCT-03-008.My brain cancer is getting worse or causing symptoms.My cancer is in an advanced stage and not just in one place.I am not pregnant or breastfeeding.I still experience side effects from past treatments, except for hair loss or acceptable lab results.
- Group 1: Dose Finding as Monotherapy - Part 1
- Group 2: Expansion as Monotherapy - Part 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what degree does UCT-03-008 endanger humans?
"Because of the limited data on safety and efficacy, UCT-03-008 was rated a 1 by our team at Power."
What aims are being pursued with this research endeavor?
"Over the course of two years, this trial seeks to identify a Recommended Phase 2 Dose (RP2D). Additional objectives include ascertaining Minimum Plasma UCT-03-008 Concentration at steady state (Cmin,ss), determining Time to Response (TTR) from start of treatment until either complete or partial response is achieved, and assessing Maximum Plasma UCT-03-008 Concentration at steady state (Cmax,ss)."
What is the maximum capacity of this research study?
"Affirmative. According to the clinicaltrials.gov webpage, this project is actively seeking participants and needs 68 people from 3 different sites. The trial was first made public on December 23rd 2021 and its information has been updated as recently as July 25th 2022."
Is enrollment currently available for this trial?
"Affirmative. According to clinicaltrials.gov, this medical study is actively looking for participants and was first published on December 23rd 2021 with the latest update occurring July 25th 2022. The research team seeks 68 individuals across 3 locations."
Share this study with friends
Copy Link
Messenger